This article is sponsored content brought to you by Virbac.
STELFONTA is a new intratumoral treatment for dogs registered for the treatment of cutaneous mast cell tumours (MCT) anywhere on the body and subcutaneous MCTs located at or distal to the elbow or the hock.
STELFONTA is a simple treatment that provides a high tumour elimination rate, rapid healing, and a speedy return to normal activity for the dog. Stelfonta contains tigilanol tiglate, which works locally by stimulating the immune system, resulting in destruction of the tumour and the tumour’s blood supply, followed by rapid healing of the site with minimal scarring.
STELFONTA starts to work within hours with tumours typically destroyed by day seven. A single treatment destroys the mast cell tumour completely in 75% of observed cases and 87% of tumours with up to two treatments. Complete healing of the resulting wound following tumour destruction by STELFONTA is typically within 6 weeks.
MCTs are the most common form of skin cancer in dogs, accounting for up to 21% of skin cancer cases and until now, surgical removal of the tumour has been standard. However, surgery can pose challenges, such as accessibility of the tumour making it difficult or impossible to obtain sufficient margins that can lead to amputation to fully remove the tumour as well as anaesthetic risks, especially in senior or brachycephalic pets. Many dog owners are also keen to avoid surgery or anaesthesia for their dogs.
Tigilanol tiglate is a biologically active pharmaceutical compound extracted from the seed of the native Australian blushwood (Fontainea picrosperma) tree found in the North Queensland rainforest. Tigilanol tiglate was discovered and developed in Australia and has been extensively researched over many years.
Do you have a case you’d like to treat with STELFONTA?
Learn more about STELFONTA and how it can change the way you treat MCTs in your practice.
Come and speak about Stelfonta® with our team at the Vet Expo 2022 stand B28 or visit the STELFONTA veterinarian website for a wealth of practical information about Stelfonta and its use in canine mast cell tumours, vet-au.virbac.com/stelfonta
1. STELFONTA Product Insert APVMA number 88412.
2. De Ridder, T., Campbell, J., Burke_Schwarz, C., et al. Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC _46). J Vet Intern Med 2021;35(1):415-429
3. Melo SR et al. VCS 2019 poster
4. McNeil EA, Prink AL, O’Brien TD. Evaluation of risk and clinical outcome of mast cell tumours in pug dogs. Vet Comp Oncol. 2006 Mar;4(1):2-8.
5. Murphy S, Sparkes AH, Blunden AS, et al. Effects of stage and number of tumours on prognosis of dogs with cutaneous mast cell tumours. Vet Rec. 2006;158(9):287-291.
6. Garrett LD. Canine mast cell tumors: diagnosis, treatment, and prognosis. Vet Med (Auckl). 2014; 5:49-58.
7. Lowe R, Gavazza A, Impellizeri JA, Soden DM, Lubas G. The treatment of canine mast cell tumours with electrochemotherapy with or without surgical excision. Vet Comp Oncol. 2017 Sep;15(3):775-784.
8. Kiupel M, Camus M. Diagnosis and Prognosis of Canine Cutaneous Mast Cell Tumors. Vet Clin North Am Small Anim Pract. 2019 Sep;49(5):819-836
9. Monteiro, Beatriz & Boston, Sarah & Monteith, Gabrielle. Factors influencing complete tumor excision of mast cell tumors and soft tissue sarcomas: A retrospective study in 100 dogs. The Canadian Veterinary Journal. La revue vt rinaire canadienne. 2011 52. 1209-14.
10. Brodbelt D. Perioperative mortality in small animal anaesthesia. Vet J. 2009 Nov;182(2):152-161